2023
Characterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels
Zhao A, Wegener M, Brooks R, Mininberg L, Helou E, Maughan A, Villanueva M. Characterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels. Health Promotion Practice 2023, 24: 1029-1038. PMID: 37439687, DOI: 10.1177/15248399231169793.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionHepatitis C virusHCV coinfectionHIV clinicDirect-acting antiviral medicationsHIV transmission risk factorsPrimary care HIV clinicClinic-level barriersHCV elimination targetsChronic HCV infectionRetrospective chart reviewPatient-level barriersClinical practice patternsMedication-assisted treatmentTransmission risk factorsIllicit substance usePatient-specific issuesLack of transportationSubstance use problemsMental health issuesHCV cureHCV infectionHCV treatmentHepatitis CUntreated patients
2022
Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
Brothers S, DiDomizio E, Nichols L, Brooks R, Villanueva M. Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment. AIDS And Behavior 2022, 27: 119-133. PMID: 35776253, PMCID: PMC9663279, DOI: 10.1007/s10461-022-03749-8.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsHIV/HCVDAA treatmentHCV treatmentHIV/HCV Co-infectionDAA treatment uptakeHCV Co-InfectionPatient-level barriersHCV diseaseAdherence supportHepatitis CActing antiviralsTreatment uptakeCo-InfectionTreatment barriersHCVTreatmentPWHAntiviralsQualitative interviewsHIVDiseaseDiagnosisPersonsUptake